Individualized survival curves improve satisfaction with cancer risk management decisions in women with BRCA1/2 mutations

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9319-9328

  Armstrong, Katrina ^a   Weber, Barbara ^a   Ubel, Peter A ^a   Peters, Nikki ^a   Holmes, John ^a   Schwartz, J Sanford ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RALOXIFENE; TAMOXIFEN;

ADULT; ANXIETY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; MASTECTOMY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; OVARIECTOMY; OVARY CANCER; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; BREAST TUMOR; DECISION MAKING; DECISION SUPPORT SYSTEM; DOUBLE BLIND PROCEDURE; GENETICS; INCIDENCE; MIDDLE AGED; PROGNOSIS; RISK MANAGEMENT; SURVIVAL; TUMOR SUPPRESSOR GENE;

ADULT; ANXIETY; BREAST NEOPLASMS; DECISION MAKING; DECISION SUPPORT SYSTEMS, CLINICAL; DOUBLE-BLIND METHOD; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; INCIDENCE; MIDDLE AGED; PATIENT SATISFACTION; PROGNOSIS; RISK MANAGEMENT; SURVIVAL ANALYSIS;

EID: 33644832185     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.06.119     Document Type: Article

References (41)

1. Warmuth MA, Sutton LM, Winer EP: A review of hereditary breast cancer: From screening to risk factor modification. Am J Med 102:407-415, 1997
2. Fisher B, Costantino JP, Wickerham D, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
3. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
4. Meier CR, Jick H: Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608-612, 1998
5. Rebbeck TR, Lynch H, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622, 2002
6. Chen CL, Weiss NS, Newcomb P, et al: Hormone replacement therapy in relation to breast cancer. JAMA 287:734-741, 2002
7. Theriault RL, Sellin RV: Estrogen-replacement therapy in younger women with breast cancer. J Natl Cancer Inst Monogr 16:149-152, 1994
8. Struewing JP, Watson P, Easton DF, et al: Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 17:33-35, 1995
9. Grundsell H, Ekman G, Gullberg B, et al: Some aspects of prophylactic oophorectomy and ovarian carcinoma. Ann Chir Gynaecol 70:36-42, 1981
10. Torgerson DJ, Bell-Syer SE: Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 285:2891-2897, 2001
11. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
12. O'Connor AM, Rostom A, Fiset V, et al: Decision aids for patients facing health treatment or screening decisions: Systematic review. BMJ 319:731-734, 1999
13. Frosch DL, Kaplan RM, Felitti VJ: A randomized controlled trial comparing internet and video to facilitate patient education for men considering the prostate specific antigen test. J Gen Intern Med 18:781-787, 2003
14. Levine MN, Gafni A, Markham B, et al: A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med 117:53-58, 1992
15. Gustafson DH, Hawkins R, Pingree S, et al: Effect of computer support on younger women with breast cancer. J Gen Intern Med 16:435-445, 2001
16. O'Connor AM, Tugwell P, Wells GA, et al: Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making 18:295-303, 1998
17. Armstrong K, FitzGerald G, Schwartz JS, et al: Using survival curve comparisons to inform patient decision making: Can a practice exercise improve understanding? J Gen Intern Med 16:482-485, 2001
18. Armstrong K, Schwartz JS, Fitzgerald G, et al: Effect of framing as gain versus loss on understanding and hypothetical treatment choices: Survival and mortality curves. Med Decis Making 22:76-83, 2002
19. Armstrong K, Schwartz JS, RandallT, et al: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: A decision analysis. J Clin Oncol 22:1045-1054, 2004
20. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059, 1997
21. Hulley S, Grady D, Bush T, et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280:605-613, 1998
22. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
23. Rebbeck TR, Levin AM, Eisen A, et al: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999
24. Thewes B, Meiser B, Hickie IB: Psychometric properties of the Impact of Event Scale amongst women at increased risk of hereditary breast cancer. Psychooncology 10:459-468, 2001
25. Weiss DS, Marmar CR: The Impact of Event Scale-Revised, in Wilson JP, KT, Solomon SD (eds): Assessing Psychological Trauma and PTSD. New York, NY, Guilford Press, 1997, pp 399-411
26. Ende J, Lewis K, Ash A, et al: Measuring patients' desire for autonomy: Decision making and information-seeking preferences among medical patients. J Gen Intern Med 4:23-30, 1989
27. Holmes-Rovner M, Kroll J, Schmitt N, et al: Patient satisfaction with health care decisions: The satisfaction with decision scale. Med Decis Making 16:58-64, 1996
28. O'Connor AM: Validation of a decisional conflict scale. Med Decis Making 15:25-30, 1995
29. Mattsson NB, Williams HV, Rickeis K, et al: Dimensions of symptom distress in anxious neurotic outpatients. Psychopharmacol Bull 5:19-32, 1969
30. Skinner CS, Schildkraut JM, Berry D, et al: Pre-counseling education materials for BRCA testing: Does tailoring make a difference? Genet Test 6:93-105, 2002
31. Stacey DO, Connor A, DeGrasse C, et al: Development and evaluation of a breast cancer prevention decision aid for higher-risk women. Health Expect 6:3-18, 2003
32. Green MJ, Peterson SK, Baker MW, et al: Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: A randomized controlled trial. JAMA 292:442-452, 2004
33. Molenaar S, Sprangers M, Rutgers EJ, et al: Decision support for patients with early stage breast cancer: Effects of an interactive breast cancer CDROM on treatment decision, satisfaction and quality of life. J Clin Oncol 19:1676-1687, 2001
34. Whelan T, Levine M, Willan A, et al: Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: A randomized trial. JAMA 292:435-441, 2004
35. Martin AM, Blackwood MA, Antin-Ozerkis D, et al: Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol 19:2247-2253, 2001
36. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002
37. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56:265-271, 1995
38. van Roosmalen MS, Stalmeier PF, Verhoef LC, et al: Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers. J Clin Oncol 22:3293-3301, 2004
39. Galtegher SM: Rethinking access in an information age. Ostomy Wound Manage 45:12-14, 1999
40. Schwartz LM, Woloshin S, Black WC, et al: The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 127:966-972, 1997
41. Assmann SF, Pocock SJ, Enos LE, et al: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355:1064-1069, 2000